PDCD1 and Hepatitis: In our study, after the commencement of treatment with PD-1 inhibitors, irAEs such as pruritus, rash, vitiligo, and hepatitis occurred in 30.1%, 24.7%, 16.1% and 8.6% of patients, respectively.